Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Efstathios Kastritis, Giovanni O. Palladini, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, Hans C. Lee, Vaishali Sanchorawala, Peter Mollee, Jin Lu, Stefan Schönland, Moshe E Gatt, Kenshi Suzuki, Kihyun Kim, M. Teresa Cibeira, Manisha Bhutani, Meral Beksac, Edward Libby, Jason Valent, Vania Hungria, Michael Rosenzweig, Naresh Bumma, Antoine Huart, NamPhuong Tran, Jianping Wang, Yuping Chen, Sandra Y. Vasey, Jordan M. Schecter, Jessica Vermeulen, Raymond L. Comenzo, Giampaolo Merlini
Institutions: National and Kapodistrian University of Athens, University of Pavia, Utrecht University, University Medical Center Utrecht, University College London, The University of Texas MD Anderson Cancer Center, Boston University, Boston Medical Center, The University of Queensland, Princess Alexandra Hospital, Peking University People's Hospital, Heidelberg University, University Hospital Heidelberg, Hadassah Medical Center, Japanese Red Cross Medical Center, Samsung Medical Center, Sungkyunkwan University, Hospital Clínic de Barcelona, Levine Cancer Institute, Wake Forest University, Istinye University, University of Washington, Cleveland Clinic, São Germano Oncologia, City Of Hope National Medical Center, City of Hope, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Hôpital Rangueil, Janssen Research & Development (United States), Janssen (Netherlands), Tufts Medical Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4405043334